Delving into the Latest Updates on Urigen N.A, Inc. with Synapse

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder Pain Syndrome. The study is randomized and double-blinded such that neither the subject nor doctor will know which drug or placebo is received.

开始日期2015-09-01

申办/合作机构

Urigen N.A, Inc.

NCT00517868 / Terminated临床2期

URG101 Pharmacodynamic and Safety Study: A Randomized, Double-blind, Placebo-controlled, Multi-center Cross-over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.

A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.

开始日期2007-08-28

申办/合作机构

Urigen N.A, Inc.

NCT00256542 / Completed临床2期

A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin

The purpose of this study is to determine whether intravesical U101 (alkalinized lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder origin.

开始日期2006-01-01

申办/合作机构

Urigen N.A, Inc.

100 项与 Urigen N.A, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Urigen N.A, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Urigen N.A, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Urigen N.A, Inc. 相关的转化医学

登录后查看更多信息